Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 11:48 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 319 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Semaglutide 1 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Conditions
Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
Interventions
Tirzepatide, Lifestyle toolkit
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Scarborough, Maine
Not yet recruiting No phase listed Observational

GLP-1 Impacts on Weight Management

NCT07829016
Conditions
Weight Management, Disordered Eating Behaviors
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

NCT06046560
Conditions
Cardiovascular Diseases, Diabetes
Interventions
SGLT2 inhibitor, GLP-1 RA, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
27 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

NCT01795235
Conditions
Healthy
Interventions
Saline, Glucagon, Placebo, Atenolol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Riverside, California • Brandon, Florida • Ocala, Florida + 15 more
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Assess Impact of Poly-L-lactic Acid on GLP1 Subjects

NCT07217743
Conditions
Laxity; Skin
Interventions
Sculptra Aesthetic
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Type 2 Diabetes, Liver Disease
Interventions
Behavioral Treatment
Device
Lead sponsor
SIPPA Solutions INC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jamaica, New York
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chula Vista, California • Escondido, California • Renton, Washington
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Type 1 Diabetes
Interventions
Sotagliflozin, Volagidemab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

NCT07758231
Conditions
GLP-1, Alcohol
Interventions
Acute Ethanol Dose
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Crohn Disease (CD)
Interventions
Tirzepatide, Standard of care treatment
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • St Louis, Missouri • New York, New York
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
G6
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Lemon Grove, California • Las Vegas, Nevada • New York, New York + 2 more
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
Tirzepatide, Resistance Exercise, Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Not applicable Interventional Results available

Four Way Crossover Closed Loop With Exercise Detection

NCT02862730
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas